Seer, Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About Seer
Laboratory Analytical Instruments, SIC 3826
Seer, Inc. is a life sciences technology company that provides platforms for unbiased, deep, and large-scale proteomic analysis. Its core offering, the Proteograph Product Suite, consists of consumable assays—including the Proteograph ONE assay—an automation instrument such as the SP200, and data analysis software. By utilizing engineered nanoparticle technology, the system enables peptide-level resolution across complex samples without relying on predefined binding epitopes. The company primarily serves researchers in proteomics and genomics across academic institutions, biopharmaceutical companies, biobanks, and clinical research organizations.
The company operates internationally, having served more than 190 customers across over 20 countries. Its primary executive offices and headquarters are located in Redwood City, California.
Summary of the business section of Seer's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Seer, Inc.
- Headquarters
- Redwood City, CA
- Address
- 3800 Bridge Parkway, Suite 102 94065
- Phone
- (650) 453-0000
- Employees
- 124, Dec 31, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, California
Stock & identifiers
- Ticker
- SEER
- Exchange
- Nasdaq
- IPO date
- Dec 4, 2020
- Shares outstanding
- 55M, Aug 5, 2026
- Public float
- $113.80M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1726445
- CUSIP
- 81578P106
- ISIN
- US81578P1066
- EIN
- 82-1153150
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Omid Farokhzad | CEO AND CHAIR, Director | 5,466,202 |
| David R. Horn | PRESIDENT & CFO | 486,650 |
| Anthony R. Bazarko | Chief Commercial Officer | 75,000 |
| Meeta Gulyani | Director | 124,043 |
| Robert Langer | Director | 821,025 |
| Isaac Ro | Director | 53,375 |
| Dipchand Nishar | Director | 75,544 |
| Terrance McGuire | Director | 343,636 |
| Nicolas H. Roelofs PHD | Director | 91,496 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Omid Farokhzad | $3.55M | $4.58M | $1.12M | $10 | – |
| FY2023 Omid Farokhzad | $5.20M | -$136.66K | $1.41M | $9 | – |
| FY2022 Omid Farokhzad | $6.74M | -$15.54M | $3.87M | $25 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 124 employees based in North America, the European Union and the United Kingdom.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 26, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 8, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 4, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 30, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 4, 2018 | Name change | Name changed from Seer Biosciences, Inc. to Seer, Inc. |